We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
Sanofi scooped up nanobody biotech Ablynx last year in a $4.5 billion deal—and now, the buyout may be starting to pay off. Cablivi, an Ablynx nanobody for a rare blood-clotting disorder, has snagged its FDA green light.